FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023080364> ?p ?o ?g. }

• W2023080364 abstract "Diagnosis of Alzheimer's disease (AD) is difficult, expensive and is only late in the disease. It requires a combination of neuropsychological testing and the exclusion of other neurological diseases. The currently best biochemical disease parameters in the cerebrospinal fluid (CSF) are Abeta, Tau, phosphorylated Tau and combinations thereof. However, there is a huge overlap in these markers between healthy controls, AD patients, and patients with other dementias and there is urgent need for the identification of easy and cost effective tests for the early identification of AD. Moreover, as new disease modification treatment paradigms for AD are being developed, there are assays needed suitable to follow the disease progression to facilitate clinical development and to show clinical efficacy of these approaches. To study the complex metabolic consequences of the disease processes and to identify candidates useful as biomarkers for diagnosis and disease progression, information-rich, non-selective but specific analytical approaches are required. Metabolic profiling offer the prospect of efficiently distinguishing individuals with particular disease or toxic states. Here we show the metabolic profile in human CSF samples of AD patients and age matched healthy controls. For the analysis we have used in total 130 CSF samples, 79 samples from AD patients and 51 age matched healthy controls. Controls and AD patients had comparable age distribution and derived from five different clinical centers in Europe. The applied combination of different metabolic profiling technologies allowed to identify and quantitate in total 343 analytes in human CSF. From these, 83 metabolites could be structurally identified. By applying univariate and multivariate statistical methods, the metabolite profiling analysis allowed for substantial differentiation of the metabolite profiles between AD patients and healthy controls showing significant differences. The statistically most significant biomarker candidates in CSF were cysteine, biotin and cortisol. Further promising biomarker candidates include tyrosine, methionine, serine, pyruvate, taurin, creatine and dopamine. With this approach we have identified candidates for biomarkers traced to metabolites or pathways specific for AD or the underlying neurodegenerative process and to be used as a starting point to for further validation in independent sample sets and subsequent studies." @default.
• W2023080364 created "2016-06-24" @default.
• W2023080364 creator A5011341820 @default.
• W2023080364 creator A5018534148 @default.
• W2023080364 creator A5047987142 @default.
• W2023080364 creator A5050127098 @default.
• W2023080364 creator A5065043368 @default.
• W2023080364 creator A5076721900 @default.
• W2023080364 creator A5082780784 @default.
• W2023080364 date "2008-07-01" @default.
• W2023080364 modified "2023-09-27" @default.
• W2023080364 title "P3-066: Metabolic profiling of Alzheimer's disease cerebrospinal fluid" @default.
• W2023080364 doi "https://doi.org/10.1016/j.jalz.2008.05.1630" @default.
• W2023080364 hasPublicationYear "2008" @default.
• W2023080364 type Work @default.
• W2023080364 sameAs 2023080364 @default.
• W2023080364 citedByCount "0" @default.
• W2023080364 crossrefType "journal-article" @default.
• W2023080364 hasAuthorship W2023080364A5011341820 @default.
• W2023080364 hasAuthorship W2023080364A5018534148 @default.
• W2023080364 hasAuthorship W2023080364A5047987142 @default.
• W2023080364 hasAuthorship W2023080364A5050127098 @default.
• W2023080364 hasAuthorship W2023080364A5065043368 @default.
• W2023080364 hasAuthorship W2023080364A5076721900 @default.
• W2023080364 hasAuthorship W2023080364A5082780784 @default.
• W2023080364 hasBestOaLocation W20230803641 @default.
• W2023080364 hasConcept C111919701 @default.
• W2023080364 hasConcept C126322002 @default.
• W2023080364 hasConcept C187191949 @default.
• W2023080364 hasConcept C2779134260 @default.
• W2023080364 hasConcept C2779651940 @default.
• W2023080364 hasConcept C2781197716 @default.
• W2023080364 hasConcept C41008148 @default.
• W2023080364 hasConcept C502032728 @default.
• W2023080364 hasConcept C54355233 @default.
• W2023080364 hasConcept C60644358 @default.
• W2023080364 hasConcept C71924100 @default.
• W2023080364 hasConcept C86803240 @default.
• W2023080364 hasConceptScore W2023080364C111919701 @default.
• W2023080364 hasConceptScore W2023080364C126322002 @default.
• W2023080364 hasConceptScore W2023080364C187191949 @default.
• W2023080364 hasConceptScore W2023080364C2779134260 @default.
• W2023080364 hasConceptScore W2023080364C2779651940 @default.
• W2023080364 hasConceptScore W2023080364C2781197716 @default.
• W2023080364 hasConceptScore W2023080364C41008148 @default.
• W2023080364 hasConceptScore W2023080364C502032728 @default.
• W2023080364 hasConceptScore W2023080364C54355233 @default.
• W2023080364 hasConceptScore W2023080364C60644358 @default.
• W2023080364 hasConceptScore W2023080364C71924100 @default.
• W2023080364 hasConceptScore W2023080364C86803240 @default.
• W2023080364 hasIssue "4S_Part_16" @default.
• W2023080364 hasLocation W20230803641 @default.
• W2023080364 hasOpenAccess W2023080364 @default.
• W2023080364 hasPrimaryLocation W20230803641 @default.
• W2023080364 hasRelatedWork W1483886510 @default.
• W2023080364 hasRelatedWork W1867806574 @default.
• W2023080364 hasRelatedWork W1997526132 @default.
• W2023080364 hasRelatedWork W2079472057 @default.
• W2023080364 hasRelatedWork W2753550874 @default.
• W2023080364 hasRelatedWork W2944072843 @default.
• W2023080364 hasRelatedWork W2944858987 @default.
• W2023080364 hasRelatedWork W3039923950 @default.
• W2023080364 hasRelatedWork W3120370246 @default.
• W2023080364 hasRelatedWork W3185661382 @default.
• W2023080364 hasVolume "4" @default.
• W2023080364 isParatext "false" @default.
• W2023080364 isRetracted "false" @default.
• W2023080364 magId "2023080364" @default.
• W2023080364 workType "article" @default.